Saroglitazar

Catalog No.S9674 Synonyms: Lipaglyn, ZYH1

For research use only.

Saroglitazar (Lipaglyn, ZYH1) is an agonist of peroxisome proliferator-activated receptor (PPAR) with EC50 of 0.65 pM and 3 nM for hPPARα and hPPARγ in HepG2 cells, respectively.

Saroglitazar Chemical Structure

CAS No. 495399-09-2

Purity & Quality Control

Choose Selective PPAR Inhibitors

Other PPAR Products

Biological Activity

Description Saroglitazar (Lipaglyn, ZYH1) is an agonist of peroxisome proliferator-activated receptor (PPAR) with EC50 of 0.65 pM and 3 nM for hPPARα and hPPARγ in HepG2 cells, respectively.
Targets
hPPARα [1]
(Cell-free assay)
hPPARγ [1]
(Cell-free assay)
0.65 pM(EC50) 3 nM(EC50)
In vitro

Saroglitazar is a novel nonthiazolidinediones (TZD) and nonfibric acid derivative designed to act as dual regulator of lipids and glucose metabolism by activating peroxisome proliferator-activated receptors (PPAR). The EC50 values of Saroglitazar assessed in HepG2 cells using PPAR transactivation assay for hPPARa and hPPARc are 0.65 pmol/L and 3 nmol/L, respectively.[1]

In vivo

In db/db mice, 12-day treatment with Saroglitazar (0.01–3 mg/kg per day, orally) causes dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED50 for these effects is found to be 0.05, 0.19, and 0.19 mg/kg, respectively with highly significant (91%) reduction in serum insulin and AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose. Significant reduction in serum TG (upto 90%) is also observed in Zucker fa/fa rats, Swiss albino mice, and in high fat -high cholesterol (HF-HC)-fed Golden Syrian hamsters. LDL cholesterol is significantly lowered in hApoB100/hCETP double transgenic mice and HF-HC diet fed Golden Syrian Hamsters. Hyperinsulinemic-Euglycemic clamp study in Zucker fa/fa rats demonstrates potent insulin-sensitizing activity. Saroglitazar also shows a significant decrease in SBP (22 mmHg) and increase (62.1%) in serum adiponectin levels in Zucker fa/fa rats. A 90-day repeated dose comparative study in Wistar rats and marmosets confirms efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans.[1]

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: HepG2 cells
  • Concentrations: --
  • Incubation Time: 20-22 h
  • Method:

    HepG2 cells are seeded in 12-well plates at a density of 400,000 cells/well in 1 mL of medium per well. Cells are transfected with PPRE3-TK-luc and 0.08 μg of the pCDNA expression vector containing the cDNA of PPARa or 0.08 μg of the pSG5 expression vector containing the cDNA of PPARc using Superfect. Cells are incubated at 37 ℃, 5% CO2: 95% O2 and after 3 h 1.0 mL of the medium containing Saroglitazar are added to the respective wells. After the incubation for 20–22 h at 37 ℃ under 5% CO2, cells are first washed with Phosphate Buffer Saline (pH 7.3- 7.4), lysed and supernatant collected for luciferase and bgalactosidase activity. The luciferase activity is determined using commercial firefly luciferase assay according to the suppliers’ instructions in white 96-well plate. The bgalactosidase activity is determined in ELISA reader at 415 nm.

Animal Research:

[1]

  • Animal Models: B6.BKS(D)-Leprdb/J(db/db) mice
  • Dosages: 0.01 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg
  • Administration: Oral gavage

Chemical Information

Molecular Weight 439.57
Formula

C25H29NO4S

Density 1.15 g/mL
CAS No. 495399-09-2
Storage 2 years 4°C liquid
Smiles CCOC(CC1=CC=C(C=C1)OCCN2C(=CC=C2C3=CC=C(C=C3)SC)C)C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04112446 Completed Drug: Saroglitazar magnesium Healthy Zydus Therapeutics Inc. September 20 2019 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Saroglitazar | Saroglitazar supplier | purchase Saroglitazar | Saroglitazar cost | Saroglitazar manufacturer | order Saroglitazar | Saroglitazar distributor